Javad Shahidi (MD, MSc)

Javad Shahidi MD, MSc developed a passion for cancer research while doing his undergraduate studies in the late 1990s. Since then, his career has been focused on cancer research both in academia and in industry. In the past 10 years, Dr Shahidi has held increasing responsibilities in Oncology Clinical Development. Dr Shahidi joined Daiichi Sankyo in 2017 in the early days of trastuzumab deruxtecan clinical development when the compound was still in Phase 1. He led the team through several key milestones including rapid expansion of clinical program and first regulatory submissions and approvals. He is currently the Vice President – Global Oncology R&D and continues to lead the trastuzumab deruxtecan program at Daiichi Sankyo as the Global Team Leader.